Drug Development

Companies Drug Development

iCD. Vertriebs GmbH, Germany

iCD. is a pioneer in LIMS and specialized in the development of software and associated consulting services for laboratories of different industry sectors such as pharma & biotechnology since 1986. More than 300 companies worldwide rely on our software solutions in R&D, production, QA/QC, sanitation more

Products Drug Development

High Performance Crossflow Cassettes Sartocon® ECO with Hydrosart® membrane

Sartocon® ECO is based on Hydrosart® ultrafilter technology that uses cross linked polymer membranes based on hydrophilic cellulose more

Protagen AG: Your reliable partner for biotherapeutical development

UNIchip® allows faster and more efficient selection of monoclonal antibodies and high affinity biotherapeutic reagents with improved specifity and stability in the development phase. more

News Drug Development

• Frost & Sullivan: Proposed regulatory uniformity to boost venture capital investments in healthcare arena

  In a shaky economic climate, where fund raising has become tight and there are decreasing opportunities to exit the market, venture capital (VC) firms have become extremely cautious in choosing their investments. This has lead to the trend of low value deals. However, segments like healthcare equipm more

• Cost of drug development reduced thanks to new technology

  De Montfort University (DMU) has come together with Ithaka Life Sciences Ltd (Ithaka), to market new technology designed to speed up and reduce the cost of the development of new drugs and medicines. A leading expert at DMU, Professor Bob Chaudhuri, has invented the technology which will provide new more

• Clavis Pharma completes patient recruitment in Phase III study with elacytarabine in patients with acute myeloid leukaemia

  Clavis Pharma ASA announced that is has reached the enrolment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine, which i more

White papers Drug Development

• Label-Free and Dynamic Monitoring of Cell-Based Assays
  

  The xCELLigence system from Roche Applied Science, originally invented by the US company ACEA Biosciences, allows for label-free and dynamic monitoring of cell-based assays. The xCELLigence system utilizes impedance readout to non-invasively quantify cellular status in real-time [1]. The cells are seeded in 96-well microtiter E-Plates with integrated microelectronic sensor arrays at the bottom of each well. more

• Real-time and Dynamic Monitoring of Virus-mediated Cytopathogenicity
  

  To understand overall infectivity, virus progression and disease onset it is important to perform a detailed examination of cytopathic effects. Depending on the type of viruses and cells, different cytopathic effects might be observed dependent on the timepoint of infection (e.g., during the growth or stationary phase) and the amount of virus used. One of the most common methods for measuring lysogenic/lytic activity of viruses is the plaque test [1]. In this assay culture plates with confluent cells that are sensitive towards the specific virus type/strain are used. Lytic activity of a virus is detected by macroscopic analysis of plaques in a confluent cell layer after staining (e.g., with crystal violet). This technique is an end-point assay and it is well-suited to determine viral titers; however, it provides no information about the onset of cytopathic effects and kinetics of the viral replication. Moreover, infection with a number of viruses (e.g., attenuated mutants) leads to the formation of small and more

• Cytokine Quantification in Drug Development
  

  Immuno-PCR (IPCR) and ElectroChemiLuminescence (ECL) are technologies for improved performance of immunoassays. The specific advantages of the different technologies, using enzymatic or electrical signal amplification, allow for tailored assay design and address several specific challenges, such as maximum sensitivity up to 1 fg/ml target cytokine, simultaneous detection of multiple antigens, and high robustness against biological matrices more

Publications Drug Development

• A toxicity risk index, an index for warning idiosyncratic drug toxicity

  Abstract Drug toxicity impedes drug development and its clinical use. In the present study, a toxicity risk index (TRI), which is an index for warning idiosyncratic drug toxicity (IDT), was proposed. The TRI of drugs was defined as a function of dose, pharmacokinetic parameters, and toxicokineti more

• When is protein binding important?

  Abstract The present paper is an ode to a classic citation by Benet and Hoener (2002. Clin Pharm Ther 71(3):115–121). The now classic paper had a huge impact on drug development and the way the issue of protein binding is perceived and interpreted. Although the authors very clearly pointed out t more

• New findings rejuvenate age-old drug development field

  Nature Medicine 19, 520 (2013). doi:10.1038/nm0513-520 Author: Cassandra Willyard more

Market studies Drug Development

• Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market

  GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market”, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdles at diff more

• XOMA Corporation – Product Pipeline Review – 2012

  Introduction Global Market Direct’s pharmaceuticals report, “XOMA Corporation - Product Pipeline Review - 2012” provides data on the XOMA Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on d more

• Orexo AB – Product Pipeline Review – 2012

  Introduction Global Market Direct’s pharmaceuticals report, “Orexo AB - Product Pipeline Review - 2012” provides data on the Orexo AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and more

Websites Drug Development